Back to Prescriptions

Off-Label and Unlicensed Prescribing

Off-Label and Unlicensed Prescribing
Prescription Medicines Editorial 23 May 2025

Finding out that a medicine is being used outside its licence is unsettling if nobody explains it. The phrase suggests something experimental or irregular. In practice it is legal, extremely common, and frequently the best-supported option available - particularly for children, in pregnancy, and in palliative care, where licensing has simply not kept pace with evidence or where trials were never commercially worth running.

Three different things

Licensed use - the medicine is used for the condition, age group, dose and route stated in its marketing authorisation.

Off-label use - the medicine is licensed, but is being used differently: another condition, a different age, a different dose, or another route. The product itself is fully authorised.

Unlicensed use - the product has no UK marketing authorisation at all. This includes imported medicines and specials, which are made to order, typically as liquids where no licensed liquid exists.

Off-label is far more common than unlicensed, and considerably less complicated.

Why it happens

Licensing follows commercial decisions, not clinical need. Extending a licence requires trials, which cost a great deal. Where a drug is old and cheap and off patent, nobody has a financial reason to fund them - even where the evidence is strong.

So amitriptyline is used widely for nerve pain and migraine prevention with good evidence and no licence for it, because it is a decades-old generic.

Children are the clearest case. Trials in children are ethically and practically difficult, so a large proportion of medicines given to children - and the majority in neonatal units - are used off-label or unlicensed. That is not carelessness; it is what the evidence base looks like.

Rare conditions rarely support a commercial licensing case.

Palliative care uses many medicines off-label, particularly by the subcutaneous route.

See nortriptyline, which is used similarly, and prazosin, used off-label for nightmares.

Off-label does not mean unevidenced

This is the point most worth grasping.

Off-label use may be supported by substantial published trial evidence, by national guidance from NICE, and by specialist consensus - none of which changes the licence, because the licence is a regulatory document owned by the manufacturer.

NICE routinely recommends off-label use where the evidence supports it.

Conversely, a licensed use is not automatically the better-evidenced one.

What the prescriber takes on

Prescribing off-label is permitted, and professional guidance sets out what is expected.

The prescriber must be satisfied there is sufficient evidence or experience to support it, must take responsibility for the decision and for monitoring, and must give you the information you need to make an informed choice.

Legal liability sits more squarely with the prescriber than it would for licensed use, which is why some clinicians are cautious and why a GP may decline to take over an unusual off-label prescription started elsewhere.

That is also why shared care agreements exist for specialist-initiated treatment.

See shared care prescribing and when a prescription is refused.

What you should be told

You should know that the use is off-label or unlicensed, why it is being recommended, and what the alternatives are.

Reasonable questions:

  • What is the evidence for using it this way?
  • Is there a licensed alternative, and why is this preferred?
  • What should I watch for, and what monitoring is needed?
  • Will my GP continue it, or does it stay with the specialist?

The patient information leaflet will describe the licensed use, so it may not mention your condition at all - which is alarming if you are not expecting it, and is not an error.

See questions to ask about a new medicine.

Specials

Unlicensed specials are usually liquids made for people who cannot swallow tablets.

Three practical points: they are expensive, sometimes dramatically so; they can take days to obtain, so order early; and the strength can vary between suppliers, so a change of supplier needs checking rather than assuming the same volume applies.

Where a licensed alternative exists in a suitable form, it is generally preferred - see trouble swallowing tablets and enalapril.

Yellow Card reporting matters more

Because off-label and unlicensed use sits outside the licensed safety data, reporting side effects is particularly valuable.

Anyone can report, including patients and carers, and for children it is worth reporting any suspected reaction however minor.

See how the Yellow Card scheme works and side effects in children.

Where to be cautious

Off-label prescribing is normal in the NHS. It is worth more scrutiny when it appears in private or online settings promoting a medicine for something it was not designed for - weight loss, hair growth, longevity or performance.

The questions are the same: what is the evidence, what monitoring is needed, and who is responsible if something goes wrong.

See what an online pharmacy should ask you.

See also Getting the Right Medicine in Pregnancy, and the Prescriptions section for more on prescriptions and pharmacy services.